Shares of Culver City-based immunotherapy company ImmunityBio Inc. had a huge runup in January, more than tripling in value ...

We recently published 10 Big Names With Effortless Double-Digit Gains. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best performers on Monday. ImmunityBio saw its share prices jump by 14.55 percent ...

A financing arrangement between biotech billionaire Dr. Patrick Soon-Shiong and ImmunityBio Inc. helped “bridge the gap” to ...

If you are wondering whether ImmunityBio's current share price is giving you a fair deal or not, this article will walk through what the numbers are really saying about its value. The stock recently ...

ImmunityBio launched the ResQ215B Phase 2 trial of a chemotherapy free, outpatient immunotherapy regimen for indolent B cell non Hodgkin lymphoma. The trial combines CAR NK cell therapy with the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.5 and $7.5 for ImmunityBio, spanning the last three months.

We recently published 10 Big Names With Painful Declines. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on ...

ImmunityBio Chairman Patrick Soon-Shiong mischaracterized talks with the FDA over the company's cancer drug, sources say.

Shiong, ImmunityBio Inc., and its leaders have defeated a shareholder challenge to a financing arrangement amid pending ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer ...

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based ...